论文部分内容阅读
作者对:200例急非淋患者进行了回顾性分析,寻找能预测诱导缓解治疗疗效的因素。按阿糖胞苷和蒽环类抗生素用药时间将患者分为“7+3”和“10+3”两组,按诱导缓解治疗的疗效分为完全缓解(CR)、顽固性白血病(RD)和其他非白血病原因死亡(Other)等三组.(一)在诱导治疗过程中死亡高危因素的分析:不论“7+3”还是“10+3”组患者年龄是最重要的因素。Other 组的年龄明显高于 CR 和 RD 组(P<0.01)。但后两组之间差异不明显。治疗前血小板计数在“10+3”组中有意义,即 Other 组血小板计数
The authors conducted a retrospective analysis of 200 patients with acute non-lymphocinoma, looking for factors that could predict the efficacy of induced remission therapy. According to the time of cytarabine and anthracycline antibiotics, the patients were divided into two groups: “7+3” and “10+3”. The patients were divided into complete remission (CR) and intractable leukemia (RD) according to the curative effect of induced remission therapy. And other non-leukemia causes (Other) and other three groups. (A) analysis of the risk factors of death in the induction process: regardless of “7 + 3” or “10 + 3” group, the age of patients is the most important factor. The age of the Other group was significantly higher than that of the CR and RD groups (P<0.01). However, the difference between the two groups was not obvious. Platelet counts before treatment were significant in the “10+3” group, ie platelet counts in the Other group.